Fed. Circ. Ruling May Affect Eligibility Of Life Sciences Patents

Law360 (November 21, 2019, 4:00 PM EST) -- The U.S. Court of Appeals for the Federal Circuit’s ruling in American Axle & Manufacturing Inc. v. Neapco Holdings LLC[1] last month might significantly impact patent eligibility for method-of-treatment and medical device claims.

Although the claims at issue in American Axle related to a mechanical technology — namely propeller shafts, or propshafts, used in automobiles — that has not received regular scrutiny under Section 101, the court nevertheless found the claims invalid as claiming a patent-ineligible natural law.

The pharmaceutical, biotech and medical industries should pay close attention to the American Axle court’s expansive application of patent ineligibility under Section 101....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS